The novel drug discovery strategies have aroused great attention in some clinical settings. To meet the challenging requirements, Creative Biolabs has built a team of experienced scientists with facilities and processes designed specifically to provide the best strategy and protocols to next-generation probiotics (NGPs) services based on Atopobium vaginae. We have accomplished a number of projects and have several Atopobium vaginae-based live biotherapeutics drugs under development.
Atopobium vaginae, a member of the family Coriobacteriaceae, is a gram-positive bacterium that has been associated with many bacterial infections in humans, including bacterial vaginosis (BV) in women. In general, Atopobium vaginae is a type of facultative anaerobe and often exists as single or pairs of short chains. Till now, different strains of Atopobium vaginae, such as CCUG 44061, CCUG 44116, CCUG 42099, and CCUG 38953T, have been isolated from specific vaginal samples. Moreover, pilot studies have shown that Atopobium vaginae are a key component for BV biofilms and its resistance to certain antimicrobials should be a major issue for improving the treatment efficacy in BV patients. Besides, numerous data have indicated that the Atopobium vaginae play an important role in preventing or treating human diseases. As a result, the Atopobium vaginae has been widely used as a new class of NGPs in specific disease treatments.
Fig.1 Atopobium vaginae culture, Gram stain. (Mendling, 2019)
Recent researchers have revealed that Atopobium vaginae are an attractive biotherapeutic agent against many disease types. Based on our integrated Live Biotherapeutics Drug Discovery platform, Creative Biolabs now offers a collection of Atopobium vaginae-based services to develop novel therapies targeting various diseases, especially for endometrial cancer.
Endometrial cancer is a kind of cancer that starts from the uterus or womb. Endometrial cancer is usually related to abnormal cell growth in the human body. Several risk factors, such as obesity and diabetes, have been confirmed that can cause the occurrence of endometrial cancer. Currently, endometrial cancer has been classified into several subtypes based on the histologic properties, including adenocarcinoma, squamous cell carcinoma, and serous carcinoma. Among them, adenocarcinoma is the most common type and has been identified in almost 80% of patients with endometrial cancer. The optimal option for treating endometrial cancer is hysterectomy, chemotherapy, and hormone therapy. In recent studies, novel live biotherapeutics targeting Atopobium vaginae have been generated for the treatment of endometrial cancer. The data derived from mice models have indicated that these drugs can inhibit tumor proliferation and induce the apoptosis of endometrial cancer cells.
By continuing to grow in response to the requirements of our clients, Creative Biolabs is dedicated to exploring novel and innovative NGPs to offer a battery of live biotherapeutic biological drug development solutions. We are proud to partner with our clients on the journey of bringing novel live biotherapeutics to the market.
Creative Biolabs utilizes unrivaled, proprietary services, advanced project life-cycle management, as well as real-time data to ensure ideal outcomes. Through our full spectrum of early discovery, nonclinical, and commercialization services, we are committed to providing the most promising Atopobium vaginae solutions for our clients. For more detailed information, please feel free to contact us.
|CAT||Product Name||Product Overview|
|LBST-073FG||Atopobium Vaginae||Atopobium Vaginae was isolated from vaginal flora from a healthy woman. It is a Gram-positive facultative anaerobic bacterial species.|
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.